The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index; 41 of the 102 sources its claims cite were checked for support.
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
Open accessAbstract
BACKGROUND: Cardiovascular disease (CVD) is a common comorbidity in type 2 diabetes (T2DM). CVD's prevalence has been growing over time. PURPOSE: To estimate the current prevalence of CVD among adults with T2DM by reviewing literature published within the last 10 years (2007-March 2017). METHODS: We searched Medline, Embase, and proceedings of major scientific meetings for original research documenting the prevalence of CVD in T2DM. CVD included stroke, myocardial infarction, angina pectoris, heart failure, ischemic heart disease, cardiovascular disease, coronary heart disease, atherosclerosis, and cardiovascular death. No restrictions were placed on country of origin or publication language. Two reviewers independently searched for articles and extracted data, adjudicating results through consensus. Data were summarized descriptively. Risk of bias was examined by applying the STROBE checklist. RESULTS: We analyzed data from 57 articles with 4,549,481 persons having T2DM. Europe produced the most articles (46%), followed by the Western Pacific/China (21%), and North America (13%). Overall in 4,549,481 persons with T2DM, 52.0% were male, 47.0% were obese, aged 63.6 ± 6.9 years old, with T2DM duration of 10.4 ± 3.7 years. CVD affected 32.2% overall (53 studies, N = 4,289,140); 29.1% had atherosclerosis (4 studies, N = 1153), 21.2% had coronary heart disease (42 articles, N = 3,833,200), 14.9% heart failure (14 studies, N = 601,154), 14.6% angina (4 studies, N = 354,743), 10.0% myocardial infarction (13 studies, N = 3,518,833) and 7.6% stroke (39 studies, N = 3,901,505). CVD was the cause of death in 9.9% of T2DM patients (representing 50.3% of all deaths). Risk of bias was low; 80 ± 12% of STROBE checklist items were adequately addressed. CONCLUSIONS: Globally, overall CVD affects approximately 32.2% of all persons with T2DM. CVD is a major cause of mortality among people with T2DM, accounting for approximately half of all deaths over the study period. Coronary artery disease and stroke were the major contributors.
Overview
CoChat Summary
TL;DR
This systematic review estimated global cardiovascular disease (CVD) prevalence among adults with type 2 diabetes (T2DM) from 57 articles covering 4,549,481 persons published 2007–March 2017. Overall CVD prevalence was 32.2%, and CVD accounted for 50.3% of all deaths in T2DM patients.
Key findings
- Among 4,549,481 persons with T2DM, overall CVD prevalence was 32.2% (53 studies, N = 4,289,140); coronary artery disease was 21.2% (42 studies, N = 3,833,200), atherosclerosis 29.1% (4 studies, N = 1,153), heart failure 14.9% (14 studies, N = 601,154), angina 14.6% (4 studies, N = 354,743), myocardial infarction 10.0% (13 studies, N = 3,518,833), and stroke 7.6% (39 studies, N = 3,901,505).
- CVD was the cause of death in 9.9% of T2DM patients (8 studies, N = 3,208,557) and represented 50.3% of all deaths (7 studies, N = 86,557); CAD deaths were 6.3% and cerebrovascular deaths 1.5%.
- Regional overall CVD prevalence was highest in North America/Caribbean (46.0%), Southeast Asia (42.5%), and Western Pacific/China (33.6%); Europe produced the most articles (46%).
- Males had higher prevalence than females for all outcomes except overall CVD, where both sexes had approximately 27%; five papers found a positive relationship between obesity and CVD, e.g., heart failure prevalence was 38.7% with BMI ≥ 30 kg/m² versus 23.4% with BMI < 30 kg/m².
Methods
- Systematic literature review following PRISMA; searched Medline, Embase, PubMed ahead-of-print, and proceedings of ISPOR, ADA, EASD, and AACE for original research published January 2007–March 2017, with no country or language restrictions; two reviewers independently searched and extracted data, with a third reviewer for quality assurance.
- Included adults ≥ 18 years with T2DM; eligible designs were prevalence studies, cross-sectional surveys, database studies, or chart reviews, with incidence studies accepted only if they provided population-based baseline and follow-up data; excluded clinical trial programs or individual pharmaceutical product studies and certain CVDs such as peripheral artery disease, rheumatic heart disease, dysrhythmias, and CABG/revascularization.
- Data were summarized descriptively with sums, averages, medians, and ranges; weighted averages were calculated for countries and IDF regions; risk of bias was assessed with the STROBE checklist; 57 articles (60 analyses) with 4,549,481 persons were included.
Limitations
- Stated by the authors: limited by available literature and article validity/quality; some results appeared only as abstracts with space limitations; incomplete or selective outcome reporting; restricted to adults ≥ 18 and T2DM only; inconsistent CVD definitions and varied outcomes across studies; prevalence studies only; varied data collection methods and time periods; possible overestimation due to sicker clinical populations and inclusion of patients with existing CVD; only 25 countries represented, with little from Africa, the Asian subcontinent, or Latin America.
- Evident in the text: no overall quantitative synthesis or meta-analysis was undertaken; one Russian study of 3,060,517 patients skewed weighted averages, so the authors calculated weighted averages with and without that study; prevalence estimates were based only on studies reporting each outcome, which may represent subgroups and may underestimate some outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
32 Valid · 1 Not valid · 37 Not checked · 73 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The weighted average of death rates from the eight studies with 3,208,557 patients with T2DM was 9.9% (95% CI 8.6–11.3%) [29–36].”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Results > CVD mortality among patients with T2DM
What the sources say
- Not checked yetcites [29] Shestakova M: Dynamics in prevalence of diabetes, diabetic complications and quality of diabetes care in Russian Federation in 2014–2015 by data of national diabetes register. In: Conference: 52nd annual meeting of the european association for the study of diabetes, EASD. 2016. p. 309.
- Not checked yetcites [30] Alwakeel JS, Sulimani R, Al-Asaad H, Al-Harbi A, Tarif N, Al-Suwaida A, Al-Mohaya S, Isnani AC, Alam A, Hammad D. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med. 2008;28:260–6. source
- Not checked yetcites [31] Cardoso C, Salles G. Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients. Braz J Med Biol Res. 2008;41:674–80. source
- Disputedcites [32] Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, Smith NL, Siscovick D. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123:556. sourceExperimental — accuracy not yet measured
Our copy of Carnethon et al. (2010) is a single prospective cohort analysis, not a pooled estimate over multiple studies: the Methods (CHS section) state it is 'a prospective cohort study... in men and women aged ≥65 years' with 'a final analysis sample included 5,784 participants' (Abstract Methods: n=5784, followed through June 30, 2005). Nothing in the paper reports eight studies, 3,208,557 patients with T2DM, or a weighted average cardiovascular death rate of 9.9% (95% CI 8.6–11.3%); its mortality results are expressed as crude rates per 1000 person-years (e.g., CHD mortality 20.1 per 1000 person-years in diabetes alone, Discussion) and as hazard ratios/PAR% (Results, Abstract Results). Searches for 'meta-analysis/pooled analysis of published studies', 'weighted average death rate', and the 9.9%/8.6–11.3% figures returned no such estimate, so the pooled, multi-study quantity attributed here conflicts with what this source actually is and reports. (LLM, conf=0.70)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [33] Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268:471–82. source
- Partly supportedcites [34] Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H, Philip S, Wild S, McCrimmon R, et al. Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia. 2015;58:716–25. sourceExperimental — accuracy not yet measured
Our copy is a single Scottish cohort (SCIDiabetes, n=121,535 people with T2DM free of CVD at baseline, mean follow-up 4.8 years), not a pooled analysis: it nowhere reports a weighted average of eight studies, 3,208,557 patients, or a 9.9% (95% CI 8.6–11.3%) figure (searches: 9.9%/weighted average/meta-analysis pooling, CVD death rate, 16,265 (13.4%) events). What it does supply is its own CVD mortality data — Results p. 4: 17,637 deaths total with 3,722 due to CVD (21% of deaths), and 16,265 (13.4%) incident fatal/non-fatal CVD events — so it is consistent with being one study contributing a CVD death rate to a pooled estimate, but the 9.9% pooled value attributed here is the citing authors' calculation, not this paper's finding. (LLM, conf=0.70)
- Not checked yetcites [35] Salinero-Fort MA, Andres-Rebollo FJ, Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, Jimenez-Garcia R, Lopez-de-Andres A, Gomez-Campelo P. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: association with chronic kidney disease. J Diab Complications. 2016;30:227–36. source
- Could not verifycites [36] Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol. 2014;13:130. sourceExperimental — accuracy not yet measured
Our copy of Menzaghi et al. 2014 is a three-cohort prospective analysis (GHS 359, HPFS 833, NHS 902; Abstract > Methods, and Study populations) of adiponectin and CV mortality, reporting annual incidence rates (1.9% NHS, 2.8% HPFS; Results) and pooled hazard ratios from a fixed-effects meta-analysis of two cohorts each (Table 2) — nothing about a weighted average death rate of 9.9% (95% CI 8.6–11.3%) across eight studies or 3,208,557 patients. Searched queries ('weighted average death rate ... 9.9%', 'crude/overall death rate percentage', 'previous meta-analysis pooling death rates in type 2 diabetes', 'percentage of participants who died') returned no passage stating or contradicting the claimed pooled figure. The paper therefore neither supports nor opposes the claim; the number likely comes from another source. (LLM, conf=0.70)
plainn = 3,208,557- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“its role for reducing cardiovascular risk has not been established as clearly in people with T2DM [11–13].”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Background
What the sources say
- Supportedcites [11] ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. source
The Background (p. 2) of our copy states that in patients with type 2 diabetes 'the effects of intensive glucose control on vascular outcomes remain uncertain,' which is exactly the level of establishment the citing sentence denies. The Results (p. 2) and Discussion (pp. 11–12) corroborate: no significant effect on major macrovascular events (HR 0.94; 95% CI 0.84–1.06; P=0.32), death from cardiovascular causes (HR 0.88; P=0.12) or all-cause death, with the authors noting the trial lacked adequate power to detect the macrovascular benefit predicted from observational data. Thus the source supports that intensive glycemic control's role in reducing cardiovascular (macrovascular) risk in T2DM is not clearly established. (LLM, conf=0.90)
- Not checked yetcites [12] UK Prospective Diabetes Study. (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352:837–53. source
- Not checked yetcites [13] Action to Control Cardiovascular Risk in Diabetes Study. Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, people with T2DM are disproportionately affected by CVD compared with non-diabetic subjects [6].”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Background
What the sources say
- Supportedcites [6] Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. source
The Abstract (Background) of our copy states that type 2 diabetes is associated with a marked increase (by a factor of two to four) in the risk of coronary heart disease, and the Discussion reports that 'diabetic subjects had much higher mortality from coronary heart disease than nondiabetic subjects, confirming previous results.' The Results (Abstract) give the concrete figures behind the disproportion (7-year MI incidence 20.2% in diabetic subjects without prior MI vs 3.5% in nondiabetic subjects without prior MI; 45.0% vs 18.8% in those with prior MI). The claim is a broad background paraphrase and is fully carried by our copy, though the underlying cohort is a Finnish population-based sample rather than a global estimate. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, patients who did not have T2DM, the death rates due to cardiovascular causes were 2.1 and 15.9%, respectively.”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Background
What the sources say
- Supportedcites [6] Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. source
Table 2 ("Incidence of Cardiovascular Events During a Seven-Year Follow-up") reports death from cardiovascular causes among nondiabetic subjects as 15.9% during follow-up in those with prior MI (n=69) and 2.1% in those without prior MI (n=1304), P<0.001, so both figures attributed to the nondiabetic group are in our copy. The Results section confirms these are the seven-year incidences in relation to diabetic status and prior-MI history. The only differences are presentation: the citing sentence reverses the order of the two groups and calls the follow-up incidences "death rates," which does not alter the substance. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a longitudinal study of 881 patients with T2DM over 10 years, van Hateren et al. [8] indicated that the hazard ratio for death due to CVD was constantly increasing each year.”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Background
What the sources say
- Partly supportedcites [8] Van Hateren KJ, Landman GW, Kleefstra N, Logtenberg SJ, Groenier KH, Kamper AM, Houweling ST, Bilo HJ. The lipid profile and mortality risk in elderly type 2 diabetic patients: a 10-year follow-up study (ZODIAC-13). PLoS ONE. 2009;4:e8464. sourceExperimental — accuracy not yet measured
The Results report 326 patients in the high age group and 555 in the low age group (881 total), with a median follow-up of 9.8 years. The Results’ “Exclusion of Early Mortality” section says the association between LDL cholesterol and mortality became more pronounced in the low age group when early deaths were excluded; it does not report that the hazard ratio for cardiovascular death rose every year of follow-up. (LLM, conf=0.87)
hedgedstates a causen = 881- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
73 more claims · 25 with their cited sources checked
Create a free account to see all 143 claims and to verify the 61 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 34
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CVD, one of the most severe systemic complications of diabetes, remains the leading cause of mortality among diabetic patients [9, 81, 82].”
From Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk factors for type 2 diabetes include overweight and obesity, physical inactivity, age, family history, race and ethnicity, history of gestational diabetes, and presence of other conditions (eg, hypertension, dyslipidemia, cardiovascular disease).9–14”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple trials have demonstrated that achieving an HbA1C less than 7% in nonpregnant adults reduces the risk of microvascular complications such as retinopathy, neuropathy, and nephropathy.14”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to lifestyle modifications including diet, exercise and weight management, metformin is generally first-line therapy for attainment of HbA1C targets.”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Results > CVD among obese vs. non-obese people with T2DM
“Five papers reported prevalence rates of CVD according to obesity status, and all of them found a positive relationship between obesity and increased prevalence rates of CVD [26, 37–40].”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Results > CVD among obese vs. non-obese people with T2DM
“However, MI prevalence rates declined thereafter with each increasing category of obesity. The highest category (BMI ≥ 40) had a prevalence rate of 5.01%, which was 27% lower than those in the lowest category (BMI < 20).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Discussion > CVD prevalence rates across regions and countries
“North America and Caribbean (46.0%; N = 4,327,503)”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Results > Included studies
“| North America and Caribbean | 344 | 8 | 170,963 | 10.9 | 13.6% | 17.2% | 29.5% | NR | 20.1% | 46.0 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Discussion > CVD prevalence rates across regions and countries
“Southeast Asia (42.5%, N = 537)”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Results > Included studies
“| Southeast Asia | 926 | 3b | 1656 | 3.1 | NR | NR | NR | NR | 29.4% | 42.5 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Conclusions
“with CAD having the highest prevalence.”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Abstract > Results
“29.1% had atherosclerosis (4 studies, N = 1153), 21.2% had coronary heart disease (42 articles, N = 3,833,200)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Out of the 57 articles, thirteen (25%) reported on the relationship between age and CVD”
§ Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 > Discussion > Age as a risk factor for CVD
Reported 25 · recomputed 22.807018
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020 · cited 1×
“The risk of bias was explored by applying the checklist from the STROBE initiative [25].”
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.07.013 · Cited by 9,909
Global status report on noncommunicable diseases 2010.
Alwan, A. (2011) · Cited by 8,494
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Research works printed but not linked: 5
- International Diabetes Federation. idf diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
- Shestakova M: Dynamics in prevalence of diabetes, diabetic complications and quality of diabetes care in Russian Federation in 2014–2015 by data of national diabetes register. In: Conference: 52nd annual meeting of the european association for the study of diabetes, EASD. 2016. p. 309.
- World Health Organization. Obesity and Overweight. Factsheet No 311. Geneva: World Health Organization; 2017.
- Cortez-Dias N, Martins S, Belo A, Fiuza M. em nome dos Investigadores do Estudio VALSIM: prevalência, tratamento e controlo da diabetes mellitus e dos factores de risco associados nos cuidados de saúde primários em Portugal. Rev Port Cardiol. 2010;29:509–37.
- Kwon H, Lim J, Shin J, Son J, Lee S, Kim S, Yoo S. A relationship of asymptomatic coronary artery disease and type 2 diabetes in acute ischaemic stroke patients; cerebral angiography and coronary angiography study. Diabetoligia. 2014;57:S26.
Cited by
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
The burden and risks of emerging complications of diabetes mellitus
Tomic, D., Shaw, J. E., & Magliano, D. J. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00690-7 · Cited by 1,163
Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T. B., Schnell, O., Standl, E., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878371 · Cited by 1,009
“At the patient level, treating patients with both CVD and T2DM resulted in a cost increase of $3418–9705 /patient/year compared with treating patients with only T2DM.40”
BackgroundInfluential
Metadata
- Authors
- Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H.
- Affiliations
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Ludwig, Craig
- Venue
- Cardiovascular Diabetology
- Published
- 2018-06-08
- Volume
- 17
- Issue
- 1
- Pages
- 83-83
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC5994068
- OpenAlex
- W2806521060
- Cited by
- 2,312
- References
- 124
- Citations by year
- 2026: 191 · 2025: 345 · 2024: 432 · 2023: 344 · 2022: 391 · 2021: 291 · 2020: 217 · 2019: 92 · 2018: 5
- FWCI
- 23.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardiovascular disease, type 2 diabetes, prevalence, coronary artery disease, heart failure, stroke, myocardial infarction, angina pectoris, cardiovascular mortality, atherosclerosis, comorbidities
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Global Health, Comorbidity, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. https://app.cochat.ai/papers/10.1186/s12933-018-0728-6
- The paper
- Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-018-0728-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

